Geron to Announce Q2 2024 Financial Results on August 8, 2024

Geron Corporation, based in Foster City, California, has announced its schedule for releasing its second-quarter 2024 financial results and business highlights. The company, which trades on Nasdaq under the ticker symbol GERN, will unveil this information before the market opens on Thursday, August 8, 2024. 

To provide further insights into these financial results and the company's activities, Geron will host a conference call at 8:00 a.m. Eastern Time on the same day. The event will include a discussion of the quarterly financial outcomes and notable business developments. Interested parties can join the live webcast and view the related presentation on Geron's website. The webcast will be archived and accessible for 30 days post-event on the company's site.

For those wishing to participate in the live webcast, registration is required and can be completed via a provided link. This allows participants to gain real-time information and engage with the company's latest updates.

Geron Corporation operates in the biopharmaceutical sector with a focus on transforming the treatment landscape for blood cancer patients. The company is known for its innovative approach in targeting telomerase activity. One of its groundbreaking products, RYTELO™ (imetelstat), is a telomerase inhibitor that has received FDA approval for treating adult patients suffering from lower-risk myelodysplastic syndromes (MDS) who are dependent on transfusions. 

The company is also advancing its research and development efforts through a pivotal Phase 3 clinical trial of imetelstat aimed at patients with myelofibrosis (MF) who have not responded to JAK inhibitors or have relapsed. Additionally, Geron is exploring the potential of imetelstat in treating other hematologic malignancies. The mechanism behind imetelstat involves inhibiting telomerase activity, which is known to be elevated in malignant stem and progenitor cells within the bone marrow. By targeting this activity, imetelstat aims to reduce the proliferation of these malignant cells and induce their death, offering a potential therapeutic pathway for patients with these challenging conditions.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!